Alivus Life Sciences has scheduled a series of one-on-one investor and analyst meetings for August 18 and 19, 2026. The company disclosed the schedule under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These engagements aim to facilitate direct interaction between the management and key market participants.

The meetings will be conducted in both in-person and virtual formats. Most sessions are scheduled to take place in Mumbai, with one session held virtually. The company noted that the schedule and mode of meetings may change due to exigencies on the part of the investors, analysts, or the company.

Meeting Schedule

The detailed schedule of the investor interactions is as follows:

Regulatory Disclosure

Alivus Life Sciences Limited submitted the intimation to the Bombay Stock Exchange and the National Stock Exchange of India. The disclosure was signed by Rudalf Corriea, the Company Secretary and Compliance Officer, on August 13, 2026. The filing references scrip code 543322 for Alivus on the BSE.

Alivus Life Sciences submitted its Business Responsibility & Sustainability Report (BRSR) for the financial year ended March 31, 2026 (FY26), to the Bombay Stock Exchange and National Stock Exchange on August 11, 2026. The filing, made pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, reveals that exports accounted for 54.4% of the company’s total turnover. The report also highlights that the company voluntarily engaged the British Standards Institution (BSI) to provide independent limited assurance on its BRSR Core Key Performance Indicators (KPIs), enhancing transparency beyond the mandatory requirements outlined in SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2025/42 dated March 28, 2025.

The disclosures are presented on a standalone basis. Alivus Life Sciences reported a turnover of ₹25,518 Million and a net worth of ₹33,321 Million for the reporting period. The company’s paid-up capital stands at ₹245.47 Million. As an active pharmaceutical ingredient (API) manufacturer, the company serves more than 700 clients globally, including the top 20 generic pharmaceutical companies worldwide, across 75+ countries and 18+ states and union territories in India.

Operational and Environmental Metrics

The company operates four manufacturing plants and two offices nationally, with one manufacturing site at Chincholi currently under construction. In terms of environmental impact, total energy consumption increased to 8,27,182.57 Gigajoules (GJ) in FY26 from 7,92,079.40 GJ in FY25. This increase was driven by higher consumption from renewable sources, which rose to 5,13,253.72 GJ from 3,13,652.22 GJ, partly due to procured steam and bio-briquettes. Conversely, energy consumption from non-renewable sources decreased significantly to 3,13,928.85 GJ from 4,78,427.18 GJ.

Greenhouse gas (GHG) emissions showed notable reductions. Total Scope 1 emissions fell to 4,284.91 metric tonnes of CO2 equivalent from 7,232.78 metric tonnes in FY25. Scope 2 emissions dropped sharply to 58,030.65 metric tonnes from 88,035.94 metric tonnes, attributed to reduced consumption of purchased steam from coal. Total water discharged was 25,806.00 kilolitres, down from 27,830.84 kilolitres in the previous year.

Employee Well-being and Safety

Alivus employed 2,284 permanent employees and 1,666 workers at the end of FY26. The workforce composition included 92.43% male and 7.57% female employees. The company reported a permanent employee turnover rate of 21.63%, compared to 20.77% in FY25. Training coverage remained robust, with 100% of workers and 88.39% of employees receiving skill upgradation training.

Safety metrics indicated some incidents during the year. The Lost Time Injury Frequency Rate (LTIFR) per one million-person hours worked was 2.01 for employees and 1.70 for workers. There were nine recordable work-related injuries among employees and twelve among workers, including one fatality in each category. No high-consequence work-related injuries excluding fatalities were reported.

Governance and CSR Initiatives

The company’s Board of Directors oversees the implementation of Business Responsibility policies, supported by a dedicated ESG Committee. Independent evaluation of policy effectiveness was conducted by Dhir & Dhir Associates. Corporate Social Responsibility (CSR) activities focused on healthcare access through Project Sampurna, benefiting 1,89,258 individuals, and education via Project ViGyasa, reaching 23,705 students. Environmental sustainability efforts included planting 35,000 new trees and maintaining 46,500 existing plantations, contributing to carbon sequestration.

What the Numbers Show

The significant reduction in Scope 2 emissions, dropping by over 34%, contrasts with the overall increase in total energy consumption. This divergence indicates a strategic shift toward renewable energy sources, such as bio-briquettes and purchased green steam, rather than merely reducing energy use. While total energy demand rose, likely due to operational scale or process changes, the carbon intensity per rupee of turnover improved, reflecting successful decarbonization efforts aligned with the company’s target to become carbon neutral by 2030.